How an Antidepressant Prescription Works in Your Body

Antidepressant prescriptions have risen steadily across most developed countries over the past decade, with average consumption across OECD nations climbing roughly a third between 2010 and 2020.¹ These medications are prescribed not just for depression but for a surprisingly wide range of conditions, and the process of choosing the right one, managing side effects, and eventually tapering off is more complex than most people expect. The science behind how they work has shifted considerably from the old “chemical imbalance” story, and several aspects of prescribing practice remain genuinely contentious.

Do Antidepressants Actually Work?

The short answer is yes, but the gap between an antidepressant and a placebo is not as dramatic as many people assume, and it depends on how severe the depression is. A large network meta-analysis covering 21 antidepressant drugs found that every single one outperformed placebo for acute treatment of major depression in adults.² That is a reassuring finding on its own. But the size of the advantage over placebo varies. Research examining pre-treatment symptom severity has shown that the benefit grows with the severity of the depression: people with severe symptoms see a substantially larger drug-versus-placebo difference than people with mild-to-moderate symptoms.³ This does not mean antidepressants are useless for milder depression, but it does help explain why some patients feel the medication “didn’t do much.”

Not all antidepressants perform equally. In head-to-head comparisons, medications like escitalopram, mirtazapine, venlafaxine, and sertraline consistently ranked among the more effective options, while drugs like reboxetine and trazodone sat near the bottom for efficacy.⁴ Tolerability is a separate dimension: some of the most effective drugs (like amitriptyline and venlafaxine) also have higher dropout rates because of side effects, while drugs like escitalopram, sertraline, and fluoxetine tend to be easier for people to stay on.⁵ Prescribers constantly balance these two considerations: what works best and what the patient can actually tolerate long enough to benefit from.

Why They Take Weeks to Kick In

One of the more frustrating aspects of starting an antidepressant is the delay. Most people are told to wait several weeks before judging whether the medication is helping. The old explanation was that antidepressants correct a “chemical imbalance” of serotonin or other brain chemicals, but if that were the full story, they should work within hours, since drug levels in the brain rise that fast. The delay suggests something else is going on.⁶

The current understanding is that antidepressants gradually trigger changes in how the brain’s neurons connect and grow. Chronic stress and depression are associated with physical changes in the brain, including shrinkage of connections between neurons in areas like the hippocampus and prefrontal cortex. Antidepressant treatment appears to protect against and partially reverse some of these changes over time.⁷ This remodeling of neural connections, rather than a simple boost of a single brain chemical, is what researchers now think accounts for both the delay and the therapeutic effect.⁸ It also helps explain why abruptly stopping an antidepressant can cause problems: the brain has adapted structurally, and reversing that adaptation takes time too.

A Surprising Amount of Off-Label Use

Many people receiving an antidepressant prescription are not being treated for depression at all. Up to about a third of all antidepressant prescriptions are for uses that fall outside the drug’s official approved indications, including chronic pain, sleep problems, eating disorders, and smoking cessation.⁹ Tricyclic antidepressants have especially high off-label prescribing rates. One study of an electronic prescribing system found that over 80% of tricyclic prescriptions were for off-label indications, driven largely by amitriptyline, which was prescribed off-label about 93% of the time, primarily for pain conditions. Trazodone prescribed for insomnia was the single most common off-label antidepressant use overall.¹⁰

The quality of evidence behind these off-label uses is uneven. In the same study, only about 16% of off-label prescriptions were supported by strong scientific evidence for that specific drug and indication. For roughly 40%, no strong evidence existed for the prescribed drug, though another antidepressant in the same class did have evidence. And for nearly 45% of off-label prescriptions, neither the prescribed drug nor any drug in its class had strong evidence for that indication.¹¹ This is worth knowing if your doctor suggests an antidepressant for something other than depression or anxiety: ask about the evidence base and whether other options have better-supported track records for your specific condition.

The growth in off-label use also partly explains rising prescription numbers. Dutch data showed that while overall antidepressant prevalence increased over a 16-year period, new prescriptions for some specific SSRIs actually decreased. The upward trend was partly sustained by longer treatment durations and expanded use for conditions like neuropathic pain and sleep disorders.¹²

Who Gets Prescribed Antidepressants

Women receive antidepressant prescriptions far more often than men. In one large retrospective cohort, antidepressant prevalence was about 28% for women and about 14% for men, and after adjusting for age, women had more than double the odds of being prescribed an antidepressant.¹³ The question is whether that gap reflects genuine differences in depression rates or something else in the prescribing system.

A Swedish cross-sectional survey found evidence that it may be a bit of both. Men reported depression at a slightly higher rate than women in that sample, yet were prescribed antidepressants at a substantially lower rate. Meanwhile, women were more likely to be prescribed antidepressants without reporting current depression, possibly because of prior diagnoses, off-label indications, or clinician bias.¹⁴ The authors framed this as potential under-treatment of men and over-treatment of women. Regardless of the explanation, if you are a man experiencing depression, this research suggests it is worth being proactive in discussing treatment rather than assuming a doctor will bring it up.

Side Effects That Make People Quit

Many people stop their antidepressant not because it fails to help their mood but because of side effects. Sexual dysfunction stands out as the issue most likely to drive non-adherence. In a study of young adult men, erectile dysfunction and inability to reach orgasm scored significantly higher than other common side effects like weight gain, nausea, and dry mouth in terms of their negative influence. With the exception of insomnia, sexual dysfunction was the side effect most likely to make participants say they would stop taking the drug.¹⁵ When participants were shown side-effect profiles and asked about their willingness to take specific drugs, they strongly preferred medications known to spare sexual function, like bupropion and mirtazapine, over SSRIs.¹⁶

What gets less attention is that sexual side effects can sometimes persist even after stopping the medication. A condition called post-SSRI sexual dysfunction (PSSD) involves symptoms like genital numbness, weak orgasm, and loss of libido that do not return to normal after the drug is discontinued.¹⁷ Reports of this have been reaching regulators since the early 1990s, though the condition was not formally described in the literature until 2006, and exact incidence rates remain unknown.¹⁸ Doctors do not routinely warn about PSSD because the risk is thought to be low, but for patients who already have concerns about sexual side effects, it is a legitimate conversation to raise with a prescriber.

Special Risks for Older Adults

Antidepressants are equally effective across age groups, but the side-effect profile shifts when prescribing to older adults, particularly around fall risk. Antidepressants contribute to falls through several pathways, including drops in blood pressure upon standing, sedation, low sodium levels, and cardiac effects.¹⁹ A nationwide cohort study found that specific drugs, including duloxetine, escitalopram, paroxetine, amitriptyline, imipramine, and trazodone, significantly increased fall-related injury risk in elderly patients.²⁰

Low sodium is another concern that is more clinically relevant in older people than younger patients. A meta-analysis of geriatric patients found that antidepressant use roughly doubled to tripled the risk of low sodium levels compared to non-use. SNRIs carried the highest risk, followed by SSRIs, while mirtazapine was associated with significantly lower risk than SSRIs.²¹ For an older adult starting an antidepressant, periodic blood work to check sodium levels is a reasonable precaution, and mirtazapine may be worth discussing with the prescriber if low sodium is a concern.

Antidepressants During Pregnancy

Deciding whether to continue or start an antidepressant during pregnancy is one of the more difficult prescribing decisions in medicine, because untreated depression carries its own risks to both mother and baby. The evidence on SSRI use during pregnancy shows a mixed picture. A large Nordic cohort study found that SSRI-exposed infants had higher rates of low Apgar scores, breathing problems, and neonatal care admission compared to infants born to mothers with depression who did not use antidepressants. At the same time, SSRI exposure was associated with lower risk of preterm birth, low birth weight, and major birth defects in that same comparison.²²

A separate population-based register study found that prenatal antidepressant use was associated with small decreases in gestational age and birth weight, along with higher risk for postnatal adaptation syndrome, a temporary cluster of symptoms in newborns that typically resolves on its own. The authors stressed that the observed associations may be partly or fully driven by the underlying illness rather than the medication itself, and that the causality question remains genuinely unresolved.²³ For someone weighing whether to stay on their antidepressant during pregnancy, the honest answer is that there are small, measurable risks in both directions, and the decision should be individualized with a doctor who can evaluate the severity of the depression against the neonatal risks.

The Black Box Warning and Youth Prescribing

Starting in 2003, the FDA warned that antidepressants could be linked to suicidal thoughts and behaviors in young people, culminating in a black box warning in 2005 for those under 18 and an expansion in 2007 to include young adults. The intended goal was to increase physician monitoring. What happened in practice was more complicated. A systematic review of studies meeting strong design criteria found no evidence that physician monitoring of suicidal thoughts actually increased. Instead, there were significant unintended drops in mental health care, including fewer depression diagnoses and fewer antidepressant prescriptions for young people. After those declines in care, studies found marked increases in suicide attempts (measured by psychotropic drug poisonings) and suicide deaths.²⁴

One analysis estimated that assuming pre-warning trends in youth suicide had continued, there may have been roughly 5,958 excess suicides nationally by 2010 among the yearly cohorts of adolescents and young adults affected by the treatment decline.²⁵ The situation is not as clean as “the warning was wrong,” though. Meta-analyses do support the finding that antidepressants are associated with increased suicidal thinking in youth, even if they do not increase completed suicides in most analyses.²⁶ The real lesson is that a well-meaning regulatory intervention can backfire if it scares patients and families away from seeking care entirely. For parents of a teenager with depression, the evidence supports careful, monitored treatment rather than avoidance of medication out of black-box-warning fear.

When the First Drug Does Not Work

A substantial proportion of people do not respond adequately to their first antidepressant. When that happens, prescribers face a choice: switch to a different drug, increase the dose, or add a second medication on top. For treatment-resistant depression, augmentation strategies that have evidence behind them include adding atypical antipsychotics, lithium, thyroid hormones, or dopaminergic compounds.²⁷ Lithium and thyroid hormones, despite being effective, remain relatively underused for this purpose.

A trial in older adults with treatment-resistant depression compared adding aripiprazole (an atypical antipsychotic), adding bupropion, or switching to bupropion alone. About 29% of patients in the aripiprazole augmentation group and 28% in the bupropion augmentation group achieved remission, compared to about 19% in the switch-to-bupropion group.²⁸ That roughly ten-percentage-point advantage for augmentation over switching is meaningful, though the overall remission rates are a reminder that treatment-resistant depression remains a genuinely difficult problem even with optimized prescribing.

Ketamine represents a fundamentally different approach. Unlike traditional antidepressants that take weeks to work, ketamine can produce rapid improvement, sometimes within hours. It has shown effectiveness specifically in treatment-resistant cases and appears to offer some protection against relapse.²⁹ A nasal-spray form (esketamine) is approved in several countries for treatment-resistant depression, though it typically requires administration in a clinical setting with monitoring. Ketamine’s mechanism appears distinct from SSRIs and SNRIs, which is part of why it can help when those drugs fail.

Combining Medication with Therapy

One of the most consistently supported findings in depression treatment is that combining an antidepressant with psychotherapy works better than medication alone. A meta-analysis found a moderately large effect favoring combined treatment over pharmacotherapy alone, translating to a number needed to treat of about four, meaning for roughly every four patients given combined treatment instead of medication only, one additional patient benefited from the combination.³⁰ The advantage was supported for major depression, panic disorder, and obsessive-compulsive disorder. If you are starting an antidepressant, therapy alongside it is not optional fluff; it meaningfully improves the odds that the medication will get you to where you want to be.

Pharmacogenomic Testing

One reason the first antidepressant trial fails for many patients is that people metabolize drugs differently based on their genetics. Pharmacogenomic testing analyzes gene variants that affect how quickly you break down certain medications, which can help a prescriber choose a drug and dose more likely to work for you specifically.³¹ A randomized trial found that patients whose prescribing was guided by pharmacogenomic testing had higher remission rates at eight weeks (24% versus 15%) and at twelve weeks (31% versus 20%) compared to patients receiving standard care, along with fewer adverse drug reactions.³² The testing is increasingly available, though not yet standard practice everywhere. If you have failed one or more antidepressants and are considering trying another, it is reasonable to ask your prescriber whether pharmacogenomic testing is available and whether it might narrow down the options.

How to Taper Safely

Stopping an antidepressant abruptly can cause withdrawal symptoms including dizziness, irritability, “brain zaps” (brief electric-shock sensations), insomnia, and a return of anxiety or depressive symptoms that may be mistakenly interpreted as relapse. The standard medical advice to “taper slowly” is correct, but the way you taper matters. Research on different tapering approaches found that reducing the dose in small daily steps along what is described as a hyperbolic curve, where the cuts get smaller as the dose gets lower, produced less withdrawal than reducing in larger weekly steps.³³ The logic is straightforward: at low doses, each milligram removed represents a proportionally larger change in brain receptor activity, so the final reductions need to be the smallest.

Specialized tapering strips, which allow patients to reduce their dose in very precise daily increments, have been validated in multiple studies as an effective way to manage withdrawal symptoms.³⁴ Paroxetine and venlafaxine are known to be particularly challenging to discontinue, and these drugs showed more withdrawal symptoms with faster tapering schedules than other antidepressants did.³⁵ If you are on one of those medications and want to stop, a taper lasting several months with progressively smaller dose reductions is the approach most likely to minimize discomfort.

Antidepressants in the Water Supply

An environmental consequence of widespread antidepressant use that most patients never consider is that these drugs end up in waterways. After being metabolized, antidepressant compounds and their byproducts pass through wastewater treatment plants, which are not designed to fully remove them, and enter rivers, lakes, and coastal waters.³⁶ Concentrations are typically low, but aquatic organisms are far more sensitive to these compounds than humans are. Laboratory studies have documented that exposure to antidepressant residues can affect survival, growth, behavior, and reproduction in fish and invertebrates.³⁷ Behavioral changes in fish, cardiovascular effects, and disrupted reproduction cycles have all been reported in the presence of antidepressant compounds at environmental concentrations.³⁸ This is not a reason to avoid a needed medication, but it is a growing environmental concern that adds another dimension to the global rise in antidepressant prescriptions, and one that wastewater treatment technology has not yet caught up with.